Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol.
Messina, Italy. In Arch Gynecol Obstet, 22 Dec 2014
We analyzed pre-treatment and post-treatment BMI, Systolic and Diastolic blood pressure, Ferriman-Gallwey score, Cremoncini score, serum LH, LH/FSH ratio, total and free testosterone, DHEA-S, Δ-4-androstenedione, SHBG, prolactin, glucose/IRI ratio, HOMA index, and resumption of regular menstrual cycles.
Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer.
Boston, United States. In J Clin Oncol, 01 Nov 2014
Therefore, we evaluated whether inclusion of plasma estradiol, estrone, estrone sulfate, testosterone, dehydroepiandrosterone sulfate, prolactin, and sex hormone-binding globulin (SHBG) improved risk prediction for postmenopausal invasive breast cancer (n = 437 patient cases and n = 775 controls not using postmenopausal hormones) in the Nurses' Health Study.
Involvement of Mammalian RF-Amide Peptides and Their Receptors in the Modulation of Nociception in Rodents.
Illkirch-Graffenstaden, France. In Front Endocrinol (lausanne), Dec 2013
They act through five G-protein-coupled receptors and each group of peptide binds to and activates mostly one receptor: RF-amide related peptide group binds to NPFFR1, neuropeptide FF group to NPFFR2, pyroglutamylated RF-amide peptide group to QRFPR, prolactin-releasing peptide group to prolactin-releasing peptide receptor, and kisspeptin group to Kiss1R.
Does Kisspeptin Belong to the Proposed RF-Amide Peptide Family?
Seoul, South Korea. In Front Endocrinol (lausanne), Dec 2013
Because of the Arg-Phe (RF) sequence at its carboxyl terminus, KISS has been proposed to be a member of the RF-amide peptide family consisting of neuropeptide FF (NPFF), neuropeptide VF (NPVF), pyroglutamylated RF-amide peptide (QRFP), and prolactin-releasing hormone (PRLH).
Mutant prolactin receptor and familial hyperprolactinemia.
More papers using
Glasgow, United Kingdom. In N Engl J Med, Dec 2013
These symptoms were not associated with pituitary tumors or multiple endocrine neoplasia but were due to a heterozygous mutation in the prolactin receptor gene, PRLR, resulting in an amino acid change from histidine to arginine at codon 188 (His188Arg).